Journal of Mahatma Gandhi Institute of Medical Sciences, 2013 Insulin analogues have revolutionized the treatment of diabetes mellitus, and the advent of newer insulin analogues have provided better glycemic control with lesser incidence of hypoglycemia.
Vishakha V Jain, Omprakash Gupta
doaj +3 more sources
Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
Indian Journal of Endocrinology and Metabolism, 2016 This study aimed to document the utility and safety of insulin degludec (IDeg) and insulin degludec aspart (IDegAsp) in persons with type 2 diabetes, observing the Ramadan fast.
Sanjay Kalra
doaj +4 more sources
Therapeutic Advances in Endocrinology and Metabolism, 2018 Background: We wanted to determine whether basal insulin requirements change when patients transition from insulin glargine U-100 (Gla-100) to insulin glargine U-300 (Gla-300) or insulin degludec.
Scott M. Pearson, Jennifer M. Trujillo
doaj +2 more sources
Insulin degludec is a new ultra-long-acting insulin analogue [PDF]
Сахарный диабет, 2014 Achieving optimal glycemic control is an important aspect of preventing and slowing the progression of diabetes-associated complications, and reducing the cost of their treatment.
Ivan Ivanovich Dedov +1 more
doaj +2 more sources
Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
Indian Journal of Endocrinology and Metabolism, 2016 Insulin degludec/insulin aspart (IDegAsp) is a modern coformulation of ultra-long-acting basal insulin degludec, with rapid-acting insulin aspart. IDegAsp provides effective, safe, well-tolerated glycemic control, with a low risk of hypoglycemia while ...
Sanjay Kalra +6 more
doaj +2 more sources
United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
Drug Design, Development and Therapy, 2017 Marc Rendell1,2 1The Rose Salter Medical Research Foundation, 2The Association of Diabetes Investigators, Newport Coast, CA, USA Abstract: Insulin degludec has been the product of a sophisticated and systematic biochemical engineering program which ...
Rendell M
doaj +1 more source
Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis [PDF]
Metabolites, 2021 Insulin degludec/insulin aspart (IDegAsp) is a novel co-formulation of 70% insulin degludec and 30% insulin aspart. The present meta-analysis was conducted to assess the efficacy and safety of IDegAsp compared with a conventional premixed insulin or ...
Shinje Moon +6 more
doaj +2 more sources
Rapid quantification of insulin degludec by immunopurification combined with liquid chromatography high-resolution mass spectrometry. [PDF]
, 2020 Insulin degludec is an ultra-long-acting insulin analogue that is increasingly being used in diabetes due to its favourable efficacy and safety profile. Thus, there is an increasing demand for a reliable and specific analytical method to quantify insulin
Prost, Jean-Christophe +6 more
core +3 more sources
Insulin Degludec/Liraglutide [PDF]
Hospital Pharmacy, 2017 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
openaire +2 more sources
Effect of tirzepatide vs insulin (insulin degludec and insulin glargine) on body weight.
, 2023 Effect of tirzepatide vs insulin (insulin degludec and insulin glargine) on body weight.
Bin Yu (14464) +8 more
core +1 more source